N-Substituted derivatives of N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine and procedure for their preparation

Abstract: The invention provides the preparation procedure for N-substituted derivatives of N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine having the general formula ( I ), where R is hydrogen, benzyl and p-nitrobenzyl group, and n is 0 , and where R is aryl, alkylaril and alkyl group with C₁ to C₄ atoms, and n is 1 , and also covers the compounds of the general formula ( I ), where R is aryl and alkylaril group, and n is 0 and 1 . According to this invention by condensation of N-substituted derivatives of N-methyl-3-phenyl-3-hydroxypropylamine ( XV ), where R is benzyl and p-nitrobenzyl group and n is 0 , and p-trifluoromethylchlorbenzene ( XVI ) prepared are N-substituted derivatives of N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine ( I ), where n and R are the same as in the compound ( XV ), which by the reaction with chloroformic acid esther ( XVII ), where R is aryl, alkylaril and alkyl group with C₁ to C₄ atoms, are converted to N-substituted derivatives of N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine ( I ), where R is the same as in the compound ( XVII ), and n is 1 , from which N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine ( I ) is prepared by basic hydrolysis and/or catalytic hydrogenolysis, when R is benzyl and p-nitrobenzyl group, and n is 0 and 1 .

Description: The invention provides compounds of the general formula (I), wherein R is hydrogen, benzyl or p-nitrobenzyl group, and n is 0, and wherein R is aryl, aralkyl or alkyl group with C 1 to C 4 atoms, and n is 1. The compound of the general formula (I), wherein R is hydrogen and n is 0 (N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine hydrochloride; Fluoxetine) is used in medicine as a selective inhibitor of serotonin uptake (Wong, D. T. et al., Drug Dev. Res., 1985, 6 ,397) and in the treatment of depressions and various types of psychical and metabolic disorders (Chovinard, G. A., Clin. J. Psychiatry, 1985, 46 , 32). Preparation of Fluoxetine is described in US-A-4,018,895, 4,194,009 and 4,314,081, GB-A-2,060,618, ES-A-556,009 and EP-A-0 380 924 and 0 391 070. According to the US pat. by bromination of 3-chloropropylbenzene (II) with bromosuccinimide 1-bromine-3-chloropropylbenzene (III) is prepared, which is then by the reaction with p-trifluoromethylphenol converted to N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylchloride (IV), from which fluoxetine (I) by the reaction with methylamine is obtained. Yields in the last two steps are moderate, irrespective of the mode in which the process is carried out. Transformation of the compound (IV) into Fluoxetine requires high reaction temperatures at which several by-products are produced, which reduces the yield significantly and creates a considerable problem in obtaining pure product by crystallization. Significant difficulties also arise during the large scale production which applies another described process involving N,N-dimethyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine (V) as an intermediate, especially because of the use of cyanogen bromide as a demethylation agent which is very dangerous under the production conditions. Similarly yields at some steps of this process according to the statements of EP-A-0 391 070 (A1) are very low, approximately 20%. In the ES-A-556 009 N-acyl and N-alkylcarbalkoxy derivatives of N-methyl-3-phenyl-3-hydroxypropylamine (VI) as intermediates are used, which by the treatment with methylsulfonylchloride are converted into the corresponding methylsulfonyl derivative (VII). After the reaction VIII with p-trifluoromethylphenol N-methyl-N-acyl-(i. e. alkylcarbalkoxy) -3-(p-trifluoromethylphenoxy)-3-phenylpropylamines (VIII) are obtained, from which Fluoxetine (I) by acid hydrolysis is prepared. This process is also rather inappropriate for preparation of fluoxetine because it is quite certain that the preparation of starting intermediate (VI), for which there is no indication as of its mode of preparation, requires at least three reaction stages. Furthermore the compound (VII) is rather unstable, and after all the yields at some steps are in general unsatisfactory. We have experimentally shown that by acid hydrolysis of the compound (VIII), prepared according to the process of this invention and under the conditions given in this patent, practically major part of the substance has not been affected by the reaction, and that Fluoxetine has been detected only by thin layer chromatography. Recently published EP-A-0 380 924 (A1) describes preparation of Fluoxetine where the starting material is ethyl benzoylacetate (IX), from which by the reduction with metal hydrides 3-hydroxy-3-phenylpropionate (X) is obtained. By further reaction with methylamine it is transformed into N-methylamide 3-hydroxy-3-phenylpropionic acid (XI). This compound (XI) is converted with p-trifluoromethylphenol in the presence of the activating substances to 3-phenyl-3-(p-trifluoromethylphenoxy)-N-methyl propanamide (XII). After the reduction with metal hydrides it gives Fluoxetine (I). The disadvantage of these processes lies in the fact that, like in already described processes, one of the starting compounds is the extremely expensive p-trifluoromethylphenol (whereas the process given in this invention uses much cheaper p-trifluoromethylchlorbenzene), and that it is very unsuitable for the large scale production because of the use of LiAlH 4 . In the GB-A-2,060,618 and EP-A-0 391 070 (A1) the starting intermediate is N-methyl-3-phenyl-3-hydroxypropylamine (XIV). Its preparation is described only in the aforementioned EP Appl. and is done by the reduction of β-(N-benzyl-N-methylamino)propiophenone (XIII) with hydrogen and Pt-Pd/C as a catalyst. Fluoxetine (I) is produced by the reaction of the compound (XIV) with p-trifluoromethylfluorobenzene in dimethylsulfoxide and NaH (Brit. pat.), and with p-trifluoromethylchlorbenzene in N-methylpyrrolidinone with potassium-tert. butoxide (EP Appl.). Disadvantage of these processes is that in the first case one of the starting raw materials is p-trifluoromethylfluorobenzene, which is approximately ten times as expensive as p-trifluoromethylchlorobenzene. In the second case the yields at the second step, according to our experience, are almost 30% lower than stated in the patent application. According to Robertson et al (J. Labelled Compd. Radiopharm., 24, (1987), 1397), N,N-dimethyl-3-(m-bromophenyl)-3-hydroxypropylamine (XV-Br) as precursor is used, which is by the reaction with p-trifluoromethylchlorobenzene (XVI) converted into N,N-dimethyl-3-(p-trifluoromethylphenoxy)-3-(m-bromophenyl)-propylamine (V-Br), from which by means of condensation with phenyl chloroformate in refluxing solution of toluene phenyl N-methyl-3-(p-trifluoromethylphenoxy)-3-(m-bromophenyl)propylamine-N-carboxylate (VIII-Br) is obtained as intermediate. After hydrolysis and catalytic debromination in the presence of deuterium or tritium 2 H- or 3 H-fluoxetine (I- 2 H- and I- 3 H) are obtained. The compounds of the general formula (I), wherein R is benzyl or p-nitrobenzyl group and n is 0, and where R is aryl, aralkyl or alkyl group with C 1 to C 4 atoms and n is 1, can be used as intermediates for preparation of Fluoxetine and other pharmaceutically active substances. A subject matter of the present invention is a process for preparation of compounds having the general formula (I), wherein R is hydrogen, benzyl or p-nitrobenzyl group, and n is 0, and wherein R is aryl, aralkyl or alkyl group with C 1 to C 4 atoms, and n is 1, wherein N-substituted derivatives of N-methyl-3-phenyl-3-hydroxypropylamine of the general formula (XV), wherein R is benzyl or p-nitrobenzyl group, and n is 0, are etherified with p-trifluoromethylchlorobenzene having the formula (XVI), to give N-substituted derivatives of N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine having the general formula (I), wherein n and R are the same as in the compound (XV), which then by the reaction with chloroformic acid ester having the general formula (XVII), ClCOOR wherein R is aryl, aralkyl or alkyl group with C 1 to C 4 atoms (e.g. methyl, ethyl, butyl group) are converted into the compound having the general formula (I), wherein R is the same as in the compound (XVII), and n is 1, from which the compound of the general formula (I), wherein R is hydrogen and n is 0, may be prepared by basic hydrolysis, and wherein the compound of the general formula (I), wherein R is hydrogen and n is 0, may additionally be prepared from compounds of formula (I), wherein R is benzyl or p-nitrobenzyl and n is 0 or 1, by catalytic hydrogenolysis, which is then transformed to corresponding salts by treatment with acids (e.g. hydrochloric or oxalic acid). According to this process, compounds of the general formula (I) can be easily prepared and high yields are achieved. A further subject matter of the present invention is a N-substituted derivative of N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine having the general formula (I), wherein R is benzyl or p-nitrobenzyl and n is 0, and R is aryl or aralkyl and n is 1. The process is characterized by the following properties: a) etherification of the compounds (XV) is carried out at a temperature of from 60 - 130°C (optimal temperature 110 - 130°C) for 3 - 10 hours in a stream of nitrogen, with 0 - 50% molar excess of p-trifluoromethylchlorobenzene (XVI) in N,N-dimethylacetamide, which are easily regenerated by distillation after the reaction is finished and can be reused in next experiment, giving the highest purity compound of formula (I), wherein n and R are the same as in the compound (XV), under the yield of up to 90%; b) the compounds (I), wherein n and R are as the above, are treated with 0 - 50% molar excess of chloroformic acid ester (XVII) in aprotic solvents (e. g. toluene, xylene, methylene chloride) at a temperature from 20-115°C for 2 - 5 hours, during which after evaporisation and crystallization from a suitable solvent (e. g. lower alcohols, petroleum ether, cyclohexane) produced are N-substituted derivatives of the same general formula (I) and of the highest purity, wherein R is the same as in the compound (XVII), and n is 1, to yield up to 92%; c) the compounds (I) wherein R is benzyl or p-nitrobenzyl group, and n is 0 or 1, are subjected to catalytic hydrogenolysis using Pd/C as a catalyst until hydrogen is theoretically used up, in the lower alcohol ( e. g. methanol, ethanol) under normal atmospheric pressure and at room temperature, and/or C1), wherein R is the same as in the compound (XVII), and n is 1, are subjected to basic hydrolysis with the use of sodium or potassium hydroxide, in diluted lower alcohol with C 1 to C 5 atoms (e. g. methanol, ethanol, 1-butanol) at 60 - 130°C (optimal temperature 110 - 130°C) during 5 - 10 hours; during which after the reaction is finished, the solvent is regenerated, treatment with hydrochloric or oxalic acid is done, and crystallization of the crystals performed from ethyl acetate or a mixture of ethyl acetate-ethanol, a pure compound of the general formula (I) is obtained, in which R is hydrogen, and n is 0 (Fluoxetine), as hydrochloride or oxalate, with yields of up to 83%. The starting compound (XV) can be prepared in quantitative yields, using alkaline solution of NaBH 4 as the agent for reduction of β-(N-benzyl-N-methylamino)propiophenone hydrochloride, which is prepared according to somewhat modified process of Mannich condensation of acetophenone, paraformaldehyde and N-benzyl-N-methylamine hydrochloride in 1-butanol or water. It has also been shown that the reaction between N,N-dimethyl derivative (V) and chloroformic acid ester (XVII) gives sometimes very stable quaternary ammonium salts, not the corresponding N-methyl-N-alkoxycarbonyl derivatives (M. Matzner, R. P. Kurkjy and R. J. Cotter, Chem. Rev., 64 (1964) 645; B. J. Calvert and J. D. Hobson, J. Chem. Soc., 1965, 2723), from which it comes out that N-benzyl- and N-(p-nitrobenzyl) derivatives of N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine are much more suitable substrates for the preparation of N-methyl-N-alkoxycarbonyl derivatives (I), than the corresponding N,N-dimethyl derivative (V). The advantage of this process, compared to the aforementioned ones, is that it offers a more economical (requires very cheap and easily provided starting raw materials), simple and safe large-scale production of the required intermediates and finished product. The process is illustrated by the below examples which do not limit it at any point. Example 1 N-benzyl-N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine The solution of N-benzyl-N-methyl-3-phenyl-3-hydroxypropylamine (2.55 g, 0.01 mol) in N,N-dimethylacetamide (8 ml) is added dropwise to the suspension of sodium hydride (0.43 g 60% oil dispersion, 0.011 mol) in N,N-dimethylacetamide (6 ml) and heated at 70 - 75°C for 5 - 10 minutes. To the obtained mixture p-trifluoromethylchlorobenzene (2.1 g, 0.0115 mol) is added and the obtained reaction mixture is heated at 130 - 135°C for 6 hours, then evaporated in vacuo and the residue dissolved in toluene (12 ml). The solution is washed with water (4 x 5 ml), organic layer filtered and then is added dropwise under mixing 2N hydrochloric acid (12 ml), and cooled at 5 - 10°C for 2 - 3 hours. The obtained white crystals are filtered and washed firstly with water (10 ml) and then with toluene (10 ml). Obtained product (3.92 g, m.p. 155 - 156°C) is mixed in 1N sodium hydroxide (20 ml) for 10 minutes at 60 - 70°C, extracted with toluene (25 ml), then the organic layer is washed with water (4 x 10 ml), filtered and evaporated in vacuo to give N-benzyl-N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine 3.59 g (90.0%) m. p. 42 - 44°C. IR (KBr): 2970w, 1620m, 1520m, 1460m, 1330vs, 1250s, 1210vs, 1175s, 1070s, 835m, 700s, cm -1 ; 1 H NMR 300 MHz (CDCl 3 ) d: 1.96 - 2.05 (2 H, m, CH 2 ), 2.22 (3 H, s, NMe), 2.39 - 2.48 and 2.57 - 2.64 (2 H, m, CH 2 ), 3.47 and 3.51 (2 H, 2d, J 12 Hz, CH 2 Ph), 5.32 (1 H, dd, CH), 6.86 (2 H, d, J 8.6 Hz, arom.), 7.22 - 7.30 (10 H, m, 2 C 6 H 5 ), 7.41 (2 H, d, J 8.6 Hz, arom.); Anal.: C 24 H 24 F 3 NO (399.46) Calc.: C 72.16; H 6.06; N 3.51% Found : C 72.18; H 6.34; N 3.54% Example 2 Methyl N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine-N-carboxylate The solution of N-benzyl-N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine (4.0 g, 0.01 mol) and methyl chloroformate (1.45 g 98%, 0.015 mol) is heated in toluene (50 ml) in a small sealed tube at 110 - 115°C for 4 hours. After the reaction solution is cooled it is firstly washed with 0.1N hydrochloric acid (4 x 10 ml) and then with 0.1N sodium hydroxide (4 x 10 ml). Finally organic layer is washed with water (4 x 10 ml), evaporated in vacuo and residue recrystallized from petroleum ether (12 ml). Yield of methyl N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine-N-carboxylate is 3.3 g (90 %), m. p. 72 - 74°C. IR (KBr): 2960w, 1710vs, 1620s, 1490m, 1410m, 1375m, 1340vs, 1275vs, 1165vs, 1070s, 845vs, 700s cm -1 ; 300 MHz 1 H NMR (CDCl 3 ) d: 2.09 - 2.10 (2 H, br, CH 2 ), 2.94 (3 H, s, NMe), 3.48 - 3.65 (5 H, br, CO 2 Me and CH 2 ), 5.13 - 5.19 (1 H, br, CH), 6.9 (2 H, d, J 8.6 Hz, arom.), 7.25 - 7.35 (5 H, m, C 6 H 5 ), 7.4 (2 H, d, J 8.6 Hz, arom.); Anal.: C 19 H 20 F 3 NO 3 (367.36) Calc.: C 62.11; H 5.49; N 3.81% Found: C 62.33; H 5.63; N 3.79% Example 3 Phenyl N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine-N-carboxylate The solution of N-benzyl-N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine (4.0 g, 0.01 mol) and phenyl chloroformate (1.76 g 98%, 0.011 mol) in methylene chloride (50 ml) is mixed at room temperature for 3 hours, and the reaction solution is treated as described in the procedure under Example 2. Yield of pure phenyl N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine-N-carboxylate is 3.71 g (propanol,86.5 %), , m. p. 83 - 84°C. IR (KBr): 2940w, 1715vs, 1620s, 1580m, 1410vs, 1340vs, 1260vs, 1190vs, 1110vs, 1050vs, 947s, 835s, 700s cm -1 ; 300 MHz 1 H NMR (CDCl 3 ) d: 2.16 - 2.35 (2H, m, CH 2 ), 3.02 and 3.09 (3H, 2s, NMe), 3.49 - 3.69 and 3.78 - 3.85 (2H, 2m, CH 2 ), 5.23 - 5.26 (1 H, br, CH), 6.84 (2 H, d, J 10.5 Hz, arom.), 6.90 - 7.35 (10 H, m, 2 C 6 H 5 ), 7.42 (2 H, d, J 10.5 Hz, arom.); Anal.: C 24 H 22 F 3 NO 3 (429.42) Calc.: C 67.12; H 5.16; N 3.26% Found: C 67.38; H 5.36; N 3.38% Example 4 p-Nitrophenyl N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine-N-carboxylate According to the procedure described under Example 2, from N-benzyl-N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine (4.0 g, 0.01 mol) and p-nitrophenyl chloroformate (2,37 g 97 %, 0,011 mol) in methylene chloride (50 ml) obtained is 4.36 g (92% amyl alcohol) of p-nitrophenyl N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine-N-carboxylate, m. p. 96-97°C. IR (KBr): 2970w, 1720vs, 1620m, 1520s, 1410m, 1350s, 1320s, 1260s, 1210s, 1160s, 1110s, 840s, 750m cm -1 ; 300 MHz 1 H NMR (CDCl 3 ) d: 2.14 - 2.35 (2 H, br, CH 2 ), 3.05 and 3.11 (3 H, 2s, NMe), 3.49 - 3.60, 3.64 - 3.74 and 3.82 - 3.92 (2 H, 3m, CH 2 ), 5.21 - 5.29 (1 H, m, CH), 6.86 (2 H, d. J 8.7 Hz, arom.), 6.91 and 6.98 (2 H, 2d, J 9 and 9 Hz, arom.), 7.14 - 7.39 (5 H, m, C 6 H 5 ), 7.43 (2 H, d, J 8.7 Hz, arom.), 8.12 and 8.19 (2 H, 2d, J 9 and 9 Hz, arom.); Anal.: C 24 H 21 F 3 N 2 O 5 (474.42) Calc.: C 60.76; H 4.46; N 5.91% Found: C 61.03; H 4.37; N 6.20% Example 5 Benzyl N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine-N-carboxylate The solution of N-(p-nitrobenzyl)-N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine (4.43 g, 0.01 mol) and benzyl chloroformate (1.98 g 95%, 0.011 mol) in methylene chloride (50 ml) at the boiling point of the solution is heated for 5 hours and then treated as described in the procedure under Example 2. The residue after evaporation of the toluene layer is chromatographed on the silica gel column, under elution with the mixture of chloroformbenzene (1 : 1) solvent to give 3.77 g (85%, R f = 0.47) benzyl N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine-N-carboxylate as oil. IR (KBr): 2965w, 1710vs, 1620s, 1460m, 1410m, 1335vs, 1255vs, 1165vs, 1115vs, 1075s, 840s, 700s cm -1 ; 300 MHz 1 H NMR (CDCl 3 ) d: 2.06 - 2.22 (2 H, br, CH 2 ), 2.93 (3 H, s, NMe), 3.44 - 3.57 (2 H, br, CH 2 ), 4.86 - 5.19 (3 H, br, CH and CO 2 CH 2 Ph), 6.80 - 7.14 (14 H, m, arom.); Anal.: C 25 H 24 F 3 NO 3 (443.45) Calc.: C 67.70; H 5.46; N 3.16% Found: C 67.45; H 5.68; N 3.05% Comparative Example N,N-dimethyl-N-benzyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylammonium chloride The solution of N,N-dimethyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine (3.23 g, 0.01 mol) and benzyl chloroformate (1.98 g 98%, 0.011 mol) in toluene (20 ml) is heated at the boiling point of the mixture for 4 hours and then cooled at 0 - 5°C for 15 hours. The obtained crystals are filtered and recrystallized from toluene (20 ml) to give 3.46 g (77%) of N,N-dimethyl-N-benzyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylammonium chloride, m. p. 154 - 155°C. IR (KBr): 3020w, 2980w, 1620s, 1525s, 1340vs, 1255vs, 1160vs, 1025vs, 1070vs, 835vs, 735s, 705s cm -1 ; 300 MHz 1 H NMR (CDCl) d: 2.70 - 2.81 (2 H, m, CH 2 ), 3.56 (6 H, s, NMe 2 ), 3.91 - 3.97 and 4.18 - 4.24 (2 H, 2m, CH 2 ), 5.16 and 5.27 (2 H, 2d, J 12.6 and 12.6 Hz, CH 2 Ph), 5.73 (1 H, dd, CH, 7.13 - 7.83 (14 H, m, arom.); Anal.: C 25 H 27 ClF 3 NO (449.93) Calc.: C 66.73; H 6.03; N 3.11; Cl 7.88% Found: C 67.02; H 6.15; N 3.06; Cl 8.08% Example 6 The solution of methyl N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine-N-carboxylate (3.67 g, 0.01 mol) and 10N sodium hydroxide (10 ml) in methanol (100 ml 90%) is heated in the sealed tube at 125 - 130°C for 4 hours and evaporated in vacuo. The residue is disolved in water (20 ml), the solution is extracted with methyl isobutyl ketone (2 x 30 ml), the collected organic layer is separated and washed with water to pH 6.5 - 7 and evaporated. The residue is disolved in ethyl acetate (50 ml), heated to 70 - 75°C and finally oxalic acid (1 g) is added to give 3.1 g (79%) fluoxetine oxalate, m. p. 182 - 183°C, which is according to its IR- and 1 H NMR spectra identical with standard sample. Example 7 The solution of ethyl N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine-N-carboxylate (3.81 g, 0.01 mol) and potassium hydroxide (4.63 g 85%, 0.07 mol) in the mixture of 1-butanol (50 ml) and water (2.5 ml) is heated at the boiling point for 5 hours, cooled, washed with water (10 ml) and then with 2N hydrochloric acid saturated with sodium chloride (2 x 10 ml) and finally the organic layer is evaporated in vacuo. The residue is disolved in the mixture of water - toluene (1 : 2, 15 ml) and cooled at 0 - 5°C for 2 - 4 hours. Obtained white crystals are filtered and washed firstly with cold water (2 x 10 ml) and then with toluene (2 x 10 ml) to give 2.9 g (83.5%) fluoxetine hydrochloride, m. p. 156 - 157°C, which is according to its IR- and 1 H NMR spectra identical with standard sample. Example 8 The solution of p-nitrophenyl N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine-N-carboxylate (4.89 g, 0.01 mol) and potassium hydroxide (3.31 g 85%, 0.05 mol) in 1-butanol (50 ml 90%) is heated at the boiling point of mixture for 3 hours, and then treated as described in the Example 6 to give 3.26 g (83%) fluoxetine oxalate, which is identical with the sample from Example 6. Example 9 The suspension of 10% Pd/C in ethanol (20 ml 96%) in the hydrogen atmosphere at normal atmospheric pressure is allowed to stay for 1.5 hours and then the solution of p-nitrobenzyl N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine-N-carboxylate (1.96 g, 0.004 mol) in ethanol (20 ml 96%) is added, and mixed in the atmosphere of hydrogen under the same conditions until theoretical quantity of hydrogen is used up. The suspension is filtered, to the filtrate 5N hydrochloric acid (2 ml) is added, evaporated in vacuo and the residue chromatographed on the column of silica gel under elution firstly with the mixture of chloroform - benzene (1 : 1), and then with the mixture of chloroform - methanol (9 : 3, R f 0.28) solvent to give fluoxetine hydrochloride, m. p. 155 - 156°C, which is identical with the sample from Example 7. Example 10 According to the procedure in the Example 10 N-benzyl-N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine hydrochloride (1.74 g, 0.004 mol) is subjected to catalytic hydrogenolysis. After that the suspension is filtered and the filtrate evaporated in vacuo, to the residue 3N sodium hydroxide (6 ml) is added, and the obtained oily suspension is extracted with toluene (4 ml). The organic layer is washed with water (2 x 2 ml), then under mixing 2N hydrochloric acid saturated with sodium chloride (4 ml) is added, and finally cooled at 0 - 5 °C for 2 - 4 hours. Obtained white crystals are filtered, washed firstly with cold water saturated with sodium chloride (2 x 2 ml), and then with toluene (2 x 2 ml). After crystallization from ethyl acetate (8 ml) fluoxetine hydrochloride, m. p. 155 - 156°C is obtained, which is identical with the sample from Example 7.

Claims: Process for the preparation of compounds having the general formula (I), wherein R is hydrogen, benzyl or p-nitrobenzyl group, and n is 0, and wherein R is aryl, aralkyl or alkyl group with C 1 to C 4 atoms, and n is 1, characterized in that N-substituted derivatives of N-methyl-3-phenyl-3-hydroxypropylamine of the general formula (XV), wherein R is benzyl or p-nitrobenzyl group, and n is 0, are etherified with p-trifluoromethylchlorobenzene having the formula (XVI), to give N-substituted derivatives of N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine having the general formula (I), wherein n and R are the same as in the compound (XV), which then by the reaction with chloroformic acid ester having the general formula (XVII), ClCOOR wherein R is aryl, aralkyl or alkyl group with C 1 to C 4 atoms (e.g. methyl, ethyl, butyl group) are converted into the compound having the general formula (I), wherein R is the same as in the compound (XVII), and n is 1, from which the compound of the general formula (I), wherein R is hydrogen and n is 0, may be prepared by basic hydrolysis, and wherein the compound of the general formula (I), wherein R is hydrogen and n is 0, may additionally be prepared from compounds of formula (I), wherein R is benzyl or p-nitrobenzyl and n is 0 or 1, by catalytic hydrogenolysis, which is then transformed into corresponding salts by treatment with acids (e.g. hydrochloric or oxalic acid). The process according to claim 1, characterized in that the basic hydrolysis is carried out with sodium or potassium hydroxide in diluted lower alcohol with C 1 to C 5 atoms (e.g. methyl, ethyl, butyl alcohol) at 60 - 130°C. The process according to claim 1, characterized in that the catalytic hydrogenolysis is carried out with Pd/C as a catalyst under normal atmospheric pressure till hydrogen is theoretically used up. N-substituted derivative of N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine having the general formula (I), wherein R is benzyl or p-nitrobenzyl and n is 0, and R is aryl or aralkyl and n is 1. The compound according to claim 4, wherein R is benzyl and n is 0. The compound according to claim 4, wherein R is p-nitrobenzyl and n is 0. The compound according to claim 4, wherein R is phenyl and n is 1. The compound according to claim 4, wherein R is p-nitrophenyl and n is 1. The compound according to claim 4, wherein R is benzyl and n is 1.

Inventors: DR CRNIC ZDRAVKO, KIRIN SRECKO, DR.CRNIC, ZDRAVKO, KIRIN, SRECKO
Applicants: PLIVA PHARM & CHEM WORKS, PLIVA FARMACEUTSKA, KEMIJSKA, PREHRAMBENA I KOZMETICKA INDUSTRIJA, DIONICKO DRUSTVO
Application year: 1994
Main classification: C07C213
IPC codes: C07C217, C07C269, A61K31, C07C213, C07C271